CClinicalTrials.gg
Not yet recruitingNCT07803718Updated Sep 4, 2026

Rotational Atherectomy and Drug-Coated Balloon Angioplasty With Embolic Protection for Superficial Femoral Artery Occlusions

An interventional study of Rotational Atherectomy With Distal Embolic Protection and Drug-Coated Balloon Angioplasty in Peripheral Artery Disease and Atherectomy in Diseased Lower Extremity Arteries, sponsored by Sakarya University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Sakarya University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Peripheral artery disease can reduce blood flow to the legs. In some patients, the superficial femoral artery, a major artery in the thigh, is completely blocked over a long segment. This study will evaluate a minimally invasive treatment for these blockages.

Approximately 60 adults who require endovascular treatment will undergo placement of a filter beyond the blockage to collect debris. Rotational atherectomy will then be used to remove part of the material causing the blockage, followed by drug-coated balloon angioplasty to widen the artery. A stent may be placed only if needed because of an inadequate treatment result or a procedure-related complication.

Participants will be evaluated by clinical examination and duplex ultrasound at 1, 3, 6, and 12 months. The main goal is to determine how often the treated artery remains open at 12 months. The study will also evaluate technical success, the need for repeat treatment, material captured by the filter, and procedure-related blockage of smaller downstream arteries.

02

Conditions studied

  • Peripheral Artery Disease
  • Atherectomy in Diseased Lower Extremity Arteries

Keywords

  • Rotational Atherectomy
  • Distal Embolic Protection
  • Endovascular Revascularization
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 18 years or older Symptomatic peripheral artery disease classified as Rutherford category 2 to 5 Chronic total occlusion of the superficial femoral artery extending from its origin toward Hunter's canal Clinical indication for endovascular treatment At least one patent distal runoff artery

Exclusion criteria

Exclusion Criteria:

  • Acute limb ischemia Severe renal impairment contraindicating iodinated contrast administration Coagulopathy Absence of a patent distal runoff artery
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Rotational Atherectomy With Drug-Coated Balloon and Embolic Protection

    Participants will undergo placement of a distal embolic protection filter followed by rotational atherectomy and drug-coated balloon angioplasty for chronic total occlusion of the superficial femoral artery. Bailout stenting may be performed in cases of flow-limiting dissection, significant residual stenosis, or another inadequate angiographic result.

    Device: Rotational Atherectomy With Distal Embolic Protection and Drug-Coated Balloon Angioplasty

Interventions

  • DeviceRotational Atherectomy With Distal Embolic Protection and Drug-Coated Balloon Angioplasty

    After successful crossing of the superficial femoral artery chronic total occlusion, a distal embolic protection filter will be deployed in the distal superficial femoral or popliteal artery. Rotational atherectomy will be performed to debulk atherosclerotic and thrombotic material, followed by drug-coated balloon angioplasty. Bailout stenting may be performed for flow-limiting dissection, significant residual stenosis, or another inadequate angiographic result.

05

What researchers measure

Primary outcomes

  1. Primary Patency of the Treated Superficial Femoral Artery Segment at 12 Months

    The proportion of participants with a patent treated superficial femoral artery segment on duplex ultrasonography, defined as a peak systolic velocity ratio of less than 2.4.

    Time frame: 12 months after the index procedure

Secondary outcomes

  1. Primary Patency of the Treated Superficial Femoral Artery Segment at 1, 3, and 6 Months

    The proportion of participants with a patent treated superficial femoral artery segment at each scheduled follow-up, assessed by duplex ultrasonography and defined as a peak systolic velocity ratio of less than 2.4.

    Time frame: 1, 3, and 6 months after the index procedure

  2. Target Lesion Revascularization

    The proportion of participants requiring repeat endovascular or surgical revascularization of the treated SFA segment.

    Time frame: Through 12 months after the index procedure

  3. Periprocedural Distal Embolization

    The proportion of participants with clinically evident or angiographically confirmed distal embolization associated with the index procedure.

    Time frame: Periprocedural

  4. Macroscopic Material Captured in the Distal Embolic Protection Filter

    The proportion of retrieved distal embolic protection filters containing macroscopically visible thrombotic or atheromatous debris.

    Time frame: Immediately after the index procedure

  5. Technical Success of the Index Procedure

    The proportion of procedures in which the target lesion is successfully crossed and treated with rotational atherectomy and drug-coated balloon angioplasty, with restoration of antegrade flow on final angiography.

    Time frame: At the end of the index procedure

06

Study locations

1 site
  • Sakarya Training and Research Hospital
    Adapazarı, Sakarya 54100, Turkey (Türkiye)
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. De-identified aggregate study results will be reported in scientific publications; however, no formal data-sharing repository or data-access mechanism has been established for this investigator-initiated, single-center study.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07803718
Lead sponsor
Sakarya University
Responsible party
ömer faruk topaloglu (Assistant Professor of Radiology, Sakarya University) — Principal investigator
First posted
Sep 4, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jun 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Sep 4, 2026

Study contacts

ÖMER FARUK TOPALOĞLU, MD
Contact
ofaruktopaloglu@gmail.com
+90 264 888 40 00

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion